<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987229</url>
  </required_header>
  <id_info>
    <org_study_id>ALKS 3831-A313</org_study_id>
    <nct_id>NCT04987229</nct_id>
  </id_info>
  <brief_title>Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects</brief_title>
  <official_title>Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with&#xD;
      schizophrenia or Bipolar I disorder&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Bipolar I Disorder</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive OLZ/SAM at a dose determined by the Investigator and based on the olanzapine dosing received in the antecedent study (ALKS 3831-A311 or ALKS 3831-A312 ENLIGHTEN-Youth)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OLZ/SAM</intervention_name>
    <description>Olanzapine and Samidorphan fixed dose coated tablet taken once daily</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>ALKS 3831</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has completed the treatment period in either the ALKS 3831-A311 or the ALKS&#xD;
             3831-A312 study within 10 days of enrolling into this extension study, or subject had&#xD;
             terminated early from Study ALKS 3831-A312 due to the clinically significant weight&#xD;
             gain criterion.&#xD;
&#xD;
          -  Subject will benefit from continued therapy with OLZ/SAM per clinical judgment.&#xD;
&#xD;
          -  Subject is able to be treated on an outpatient basis.&#xD;
&#xD;
          -  Subject must not be a danger to self or others (per Investigator judgement) and has&#xD;
             family support available to be maintained as an outpatient.&#xD;
&#xD;
          -  Subject's parent(s)/legal guardian(s) is considered reliable by the Investigator and&#xD;
             has agreed to provide support to the subject to ensure compliance with study&#xD;
             treatment, visits, and protocol procedures.&#xD;
&#xD;
          -  Subject agrees to abide by the contraception requirements specified in the protocol&#xD;
             for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject poses a current suicide risk as assessed by the Investigator or as confirmed&#xD;
             by the baseline Columbia-Suicide Severity Rating Scale by a response of &quot;Yes&quot; to&#xD;
             question numbers 4 or 5 with ideation or suicidal behavior since the last visit.&#xD;
&#xD;
          -  Subject has any finding that in the view of the Investigator or Medical Monitor would&#xD;
             compromise the safety of the subject or affect their ability to fulfill the protocol&#xD;
             visit schedule or visit requirement.&#xD;
&#xD;
          -  Subject is currently taking medications that are contraindicated with olanzapine use&#xD;
             or exhibit drug-interaction potential with olanzapine&#xD;
&#xD;
          -  Subject has a positive test for opioids.&#xD;
&#xD;
          -  Subject has a positive urine pregnancy test, is currently pregnant or breastfeeding,&#xD;
             or plans to become pregnant or begin breastfeeding at any point during the study and&#xD;
             for 90 days after any study drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David McDonnell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar I Disorder</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Samidorphan</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Olzanzapine</keyword>
  <keyword>Safety</keyword>
  <keyword>LYBALVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

